Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Aralez Pharmaceuticals (ARLZ) Share Price

Media headlines about Aralez Pharmaceuticals (NASDAQ:ARLZ) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aralez Pharmaceuticals earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave news headlines about the company an impact score of 44.3716055295586 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Aralez Pharmaceuticals (NASDAQ ARLZ) opened at $1.50 on Monday. The company has a market capitalization of $97.65, a PE ratio of -0.89 and a beta of 1.31. Aralez Pharmaceuticals has a one year low of $0.95 and a one year high of $4.86. The company has a debt-to-equity ratio of 4.64, a quick ratio of 0.92 and a current ratio of 1.00.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($0.37) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.02. Aralez Pharmaceuticals had a negative return on equity of 118.13% and a negative net margin of 112.89%. The company had revenue of $24.30 million for the quarter, compared to analysts’ expectations of $22.87 million. During the same quarter in the previous year, the firm posted ($0.32) earnings per share. The firm’s quarterly revenue was up 78.7% on a year-over-year basis. sell-side analysts expect that Aralez Pharmaceuticals will post -1.54 EPS for the current year.

In other Aralez Pharmaceuticals news, Director Arthur S. Kirsch bought 50,000 shares of the company’s stock in a transaction dated Friday, December 8th. The shares were acquired at an average cost of $1.47 per share, with a total value of $73,500.00. Following the completion of the transaction, the director now owns 271,609 shares in the company, valued at $399,265.23. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 6.70% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Week Herald and is owned by of Week Herald. If you are viewing this news story on another site, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this news story can be read at

About Aralez Pharmaceuticals

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Insider Buying and Selling by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)

Receive News & Ratings for Aralez Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply